Monroe1
2 hours ago
Liability or no liability. The people of the world are reacting to the lies. Pfizer/Moderna will pay for their deceit and all those who assisted in this human assault whether they were part of it originally or just taking the money or to maintain their jobs.
FOCAL POINTS (Courageous Discourse) cross-posted a post from Truth, Investing, and Freedom
Peter A. McCullough, MD, MPHMar 2 · FOCAL POINTS (Courageous Discourse)
Colleagues
Please see this important release on toxic vaccine lots in Canada and the coverup by British Columbia officials as Dr Hoffe and others worked to expose the problem.
Peter A. McCullough, MD, MPH
Review of FOI F23-1799 and BC Public Health’s Handling of COVID-19 Vaccines AEFI – Part 1
Lex Acker
Mar 2
READ IN APP
Background
In April 2023, Lee Turner, of Doak Shireff Lawyers LLP, took over conduct of the defence of Dr. Charles Hoffe vs. the College of Physicians and Surgeons of BC. Mr. Turner subsequently filed a Freedom of Information (FOI) request (F23-1799) with the Provincial Health Services Authority (PHSA) to obtain data on Adverse Events Following Immunization (AEFI). FOI F23-1799 can be accessed at this link.
FOI F23-1799 was released in June 2024 and comprised over 1,300 pages of internal emails between BC CDC staff, Bonnie Henry, Reka Gustafson, and Monika Naus (then head of BC CDC), along with dozens of AEFI reports.
Upon reviewing FOI F23-1799, I noted key elements: discussions of AEFIs in emails, screenshots of non-public AEFI reports available through an intranet, and public-facing AEFI reports presented in chronological order. This arrangement made it possible to determine what BC public health officials like Bonnie Henry, the BC CDC and all 50+ medical health officers scattered over BC health authorities knew and when they knew it.
I reached an unsettling conclusion: BC CDC had manipulated the definition of Serious Adverse Events Following Immunization to lower the reported rates of Serious AEFIs in public-facing reports, thereby concealing the true risks associated with COVID-19 vaccines. I publicly shared this finding on June 14, 2024, in a comment on Byram Bridle’s post titled Breaking News: BC Centre for Disease Control Caught Lying and Withholding Important Public Health Data.
While my expertise is not in medical science, I specialize in detecting and documenting corporate and institutional misconduct. My background is in financial statement analysis. I worked as a hedge fund research analyst and compliance officer for a boutique investment firm. I have about 15 years of independent financial research and analysis experience. My focus is uncovering white-collar fraud. I’m not a forensic accountant by any measure; I’m just someone with somewhat odd proclivities for large sets of unstructured data and enjoy immersing myself in new topics.
The Case Against Dr. Hoffe
The College of Physicians and Surgeons of BC cancelled its February 11, 2022 citation against Dr. Hoffe on February 5, 2025. According to one media outlet, this was done because of a "material change of circumstances."
The College accused Dr. Hoffe of professional misconduct; specifically spreading misinformation about COVID-19 vaccines. Here’s an excerpt of the College’s accusations:
“… publicly expressing that the COVID-19 vaccinations cause microscopic blood clots that cause serious neurological harm, female infertility, and a high number of deaths that is not recognized by public health; …”
Many other doctors were publicly denouncing the COVID-19 vaccines and were persecuted by the College. However, the level of persecution against Dr. Charles Hoffe is particular. The College retained eight experts against Dr. Hoffe. Why is that?
In early 2021, Dr. Hoffe submitted a temporally- and vaccine lot-associated cluster of 11 AEFI reports to Interior Health, 10 of which involved Moderna lot #300042698, administered between January 18 and February 5, 2021.
As Dr. Hoffe began filing AEFI reports in early 2021—most notably in April and May— and went on public tours in BC warning the public about the harms of COVID-19 vaccines his actions posed a direct threat to a state narrative that sought to suppress information about vaccine-related harm. His findings challenged the political and ideological foundation underpinning the mass vaccination program and the totalitarian controls over the population that came along with it.
The evidence in FOI F23-1799 suggests that Bonnie Henry, the BC CDC, all health authorities, and all 50+ Medical Health Officers in BC were fully aware of these issues. Dr. Hoffe’s real "offence" was exposing what the BC government concealed from the public since early 2021. Dr. Hoffe’s AEFI reports constituted a cluster of AEFI associated with unexpected harms which required public health authorities to investigate and disclose to the public.
This post, and a few more to come, will cover my findings and analysis of how BC public authorities handled the COVID-19 vaccine AEFIs.
BC Public Health Officials Early Knowledge of Harms Associated with the COVID-19 Vaccines
Higher AEFI Rates Associated with Higher mRNA Content
January 28th, 2021 - P. 18, FOI F23-1799:
Above, is the upper half of an email to Bonnie Henry where Monika Naus, Medical Director of the BC CDC, states: “A history of anaphylaxis to a dose of the vaccine is a contraindication to receipt of future doses.” This is important to keep in mind as I will relate that statement to data in non-public AEFI reports further down.
Monika Naus, briefed Bonnie Henry and Martin Lavoie, Chief Medical Health Officer of Interior Health, on the observation that ‘cellulitis’ events occurred at “an appreciably higher rate” with the Moderna vaccine compared to Pfizer. However, she seems to downplay the significance of these reported cases.
Monika Naus explained that the higher rate of AEFIs associated with Moderna was consistent with its higher mRNA content. Her statements indicate an awareness that, since Pfizer and Moderna vaccines share similar structures, the key difference lies in mRNA dosage. Below is the lower half of Monika Naus’ email to Bonnie Henry.
Above, Monika Naus reports to Bonnie Henry the death of an inmate and two temporally associated thrombocytopenia reports. A few months later, the BC CDC will deny in public-facing AEFI reports that they received thrombocytopenia cases. Monika Naus stresses with capital letters that this is NOT being seen in the US analytic data comparing rates, indicating that she’s worried and that these findings in BC were unexpected. The link at the bottom of the above email is to slide deck containing V-Safe data.
Misleading Public Reporting of Thrombocytopenia and Serious AEFIs
In the above email of January 28th, 2021 to Bonnie Henry, Monika Naus refers to two cases of temporally associated thrombocytopenia. Later, on p. 206 of F23-1799, the non-public AEFI report of March 25th, 2021, showed 3 cases of thrombocytopenia.
May 1st, 2021 – P. 287, FOI F23-1799:
Below, the public-facing BC CDC AEFI report from December 13th, 2020, to May 1st, 2021 stated:
“No safety signals have been identified in the reports received in BC to date”
“Serious events have not been reported at rates higher than expected compared to background rates.”
“There have been no reports of thrombosis with thrombocytopenia syndrome (TTS) reported in BC to date;”
The above-highlighted statements from the public-facing BC CDC AEFI report of May 1st, 2021, are misleading when compared to the non-public BC CDC AEFI reports.
March 25th, 2021 – P. 205, FOI F23-1799:
Below,
The non-public BC CDC AEFI report shows 523 Total AEFI, 144 Serious AEFI, 94 Anaphylaxis AEFI and their respective rate per 100,000 doses are 84.37, 23.23, and 15.16.
Serious AEFI represent 27.5% of Total AEFI.
The COVID-19 vaccine Serious AEFI rate is unexpectedly 15.7 times greater than the historic flu vaccine Serious AEFI rate (background rate). This is an obvious safety signal.
The total AEFI rate of the historic flu is 6.5 per 100,000 doses
The Serious AEFI rate of the historic flu is 1.48 per 100,000 doses
Pandemic of the Newly Injected
In the Monika Naus email of January 28th, 2021, there’s a link to a CDC slide deck that is no longer available for some reason. I managed to recover it. Its 7th slide shows AEFI from the V-Safe database that took New York Attorney Aaron Siri 18 months to obtain via the US courts. The slide shows US AEFI data as of January 14th, 2021, and the slide deck was published on January 27th, 2021.
Above is the sample size, which makes the numbers below extremely significant. The “All vaccines” red rectangle in the table below means All COVID-19 vaccines.
The above statistics were compiled from self-reporting recipients of the COVID-19 vaccines within 7 days after receipt of the vaccine. This is what you can expect within 7 days. I wonder if this is why Public Health Officials in BC and around the globe required you to wait between 14 days and 21 days before they would categorize you as being vaccinated?
*** The V-Safe data in the table above was in the possession of Bonnie Henry and the BC CDC since January 27th, 2021. ***
Comparing the AEFI rates between the first and second doses of Pfizer, it is evident that toxicity and harms increase with additional doses. We also see that when comparing dose 1 of Pfizer and Moderna, Moderna is more toxic than Pfizer. If the above level of risks had been disclosed to the public, it would have likely caused massive vaccine hesitancy in most sane people.
You can imagine that a large percentage of the population started having one or more of these very common reactions very early in the COVID-19 vaccine rollout and, believing the vaccines to be safe, attributed them to COVID-19 itself.
*** The COVID-19 vaccines caused a massive immediate surge in demand for healthcare. MASS INJURIES ***
The works of Denis Rancourt and Ed Dowd are what immediately come to my mind in support of mass injuries. Ed Dowd pointed out that the US Department of Labor maintained statistics on disabled people. Coinciding with the COVID-19 vaccine rollout we see a massive surge of people self-reporting as disabled. Here are the monthly year-over-year changes in disabilities observed by Ed Dowd.
Review of FOI F23-1799 and BC Public Health’s Handling of COVID-19 Vaccines AEFI – Part 1
Lex Acker
Mar 2
https://substack.com/app
axelvento
2 weeks ago
TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status
TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1) and by 14 months in patients selected for HRR mutations (Cohort 2) versus standard of care XTANDI
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The TALAPRO-2 results will be presented at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium in San Francisco and featured in the ASCO GU official Press Program.
The TALAPRO-2 study evaluated two sets of patients, unselected (cohort 1) and selected for HRR gene-mutations (cohort 2). Overall survival was a prespecified, alpha-protected key secondary endpoint. After more than four years of median follow-up (52.5 months), the median OS in cohort 1 was 45.8 months with TALZENNA in combination with XTANDI, and 37.0 months with XTANDI and placebo (Hazard Ratio [HR] of 0.80; 95% Confidence Interval [CI], 0.66-0.96; p=0.015), representing a 20% reduction in the risk of death. This represents a nearly 9-month gain in median OS versus standard of care XTANDI. Data from cohort 1 will be presented today at ASCO GU in an oral presentation (Abstract LBA18) by Dr. Neeraj Agarwal, global lead investigator for TALAPRO-2.
In Cohort 2, a statistically significant and clinically meaningful improvement in OS was observed in patients with HRR-mutated mCRPC. At a median follow-up of 44.2 months, the median OS was 45.1 months with TALZENNA in combination with XTANDI, and 31.1 months with XTANDI and placebo (HR of 0.62; 95% CI, 0.48-0.81; p=0.0005), a 38% reduction in the risk of death. This result represents a 14-month gain in median OS versus standard of care XTANDI in a patient population with a historically poor prognosis. The OS improvement in the HRR-mutated population was observed in patients in both BRCA and non-BRCA gene alterations. Dr. Karim Fizazi, Institut Gustave Roussy, University of Paris-Saclay will share data from Cohort 2 at ASCO GU today (Abstract LBA141).
“Since its approval, TALZENNA in combination with XTANDI has redefined the standard of care for those living with homologous recombination repair gene-mutated mCRPC. These latest data from TALAPRO-2 are extremely compelling, demonstrating that the combination significantly extended overall survival, in patients selected and unselected for HRR gene alterations, potentially shifting the treatment paradigm for all men living with mCRPC,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “Although definitive conclusions cannot be drawn across studies, these results appear to represent the longest median overall survival reported in a randomized, controlled Phase 3 trial in mCRPC. We look forward to continuing to work with global authorities to potentially update the TALZENNA label with these results.”
“TALAPRO-2 is the first study demonstrating a significant and clinically meaningful survival benefit using a combination of PARP and androgen receptor inhibitors in mCRPC,” said Neeraj Agarwal, M.D., FASCO, Professor and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute, University of Utah, and global lead investigator for TALAPRO-2. “Survival rates in metastatic castration-resistant prostate cancer are poor due to the advanced and aggressive stage of the disease. Today’s results demonstrate the potential for TALZENNA in combination with XTANDI to be a practice-changing treatment to help improve patient survival in mCRPC.”
At the time of the final analysis, updated radiographic progression free survival (rPFS) and other secondary efficacy endpoints demonstrated maintained clinical benefit in both cohorts and were consistent with the primary analyses previously reported and published in The Lancet and Nature Medicine.
In addition to the FDA, these data have been shared with the European Medicines Agency (EMA) and other global health authorities to support potential updates of the approved labels for TALZENNA.
The safety profile of TALZENNA plus XTANDI was generally consistent with the known safety profile of each medicine. The most common all-cause adverse events in the TALZENNA group (=30% of patients) were anemia, neutropenia, and fatigue, and the most common (=10% of patients) grade 3–4 adverse events were anemia (49%) and neutropenia (19.3%). Adverse events were generally manageable with dose modification and supportive care.
https://www.biospace.com/press-releases/pfizers-talzenna-in-combination-with-xtandi-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer
axelvento
3 weeks ago
A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating castration-resistant prostate cancer.
Pfizer’s experimental drug mevrometostat cut disease progression rates in half in combination with standard hormone therapy, according to an article describing data from a Phase I trial of metastatic castration-resistant prostate cancer that appeared on Monday morning on the website for the ASCO Genitourinary Cancers Symposium.
The only issue is that the team from Pfizer wasn’t going to speak about the data until Thursday. Later in the day Monday, the conference published a full study abstract.
In addition to reducing disease progression rates, mevrometostat cut the risk of death by 49% in trial participants, all of whom had already received hormone treatment and one round of chemotherapy, according to reporting from Endpoints News.
Adverse effects were diarrhea (78% of patients), decreased appetite (58.5%) and dysgeusia (58.5%).
Pfizer is currently recruiting for two Phase III trials, MEVPRO-1 and MEVPRO-2, testing mevrometostat, an inhibitor of the oncoprotein EZH2, in prostate cancer as well.
Castration-resistant prostate cancer is a common form of prostate cancer, often treated with androgen deprivation therapy and chemotherapy.
The results, although announced prematurely, should be welcome news for Pfizer. Analysts were already buoyant on the company, with Guggenheim analysts writing in an investor note early Monday morning, before the leak, that Pfizer beat their fourth quarter 2024 expectations as well as consensus estimates.
Pfizer has a number of critical updates from its oncology pipeline coming down the pike this year. Phase III data for vepdegestrant in treating breast cancer and danuglipron for obesity are expected later this quarter, as well as Padcev in combination with pembrolizumab for bladder cancer sometime this year. On Monday, Pfizer announced data showing that Padcev in combination with Merck’s Keytruda reduced the risk of death by 49% in urothelial cancer compared to chemotherapy.
https://www.biospace.com/drug-development/leaked-conference-article-shows-pfizers-positive-phase-i-prostate-cancer-data
https://meetings.asco.org/abstracts-presentations/243221
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
biotech_researcher
5 days ago
Lime Time
6 days ago
hubb1
6 days ago
Vexari
6 days ago
DewDiligence
6 days ago
Hot Features
Premium
